OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Rosai-Dorfman-Destombes disease: the decisions you may face

5 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

4 options

Excisional biopsy with immunohistochemistry and MAPK pathway sequencing; FDG-PET/CT; MRI where neurological disease is suspected; immunoglobulins and autoimmune screen.

The options, in plain words

Histopathology means looking at cancer cells under a microscope, and immunohistochemistry stains them for specific proteins. Together they are still the foundation of every diagnosis.

  • Cheap, fast, universal
  • Companion diagnostic for most targeted drugs

Sequencing hundreds of cancer genes at once from a biopsy to find the mutations a drug can target.

  • One test, all actionable alterations
  • Trial matching
FDG PETStandard of care

FDG PET is the standard PET scan. A radioactive sugar shows which tissues are burning glucose fast, which most cancers do.

  • Universal availability
  • Decades of validation
MRIStandard of care

MRI uses a strong magnet and radio waves, with no ionising radiation, to picture soft tissue in finer contrast than CT, so it is the standard scan for brain tumours, prostate, rectal cancer staging, liver lesions and breast screening in high-risk women. It is slow, expensive and blurred by movement.

  • No ionising radiation
  • Best soft-tissue and brain imaging
  • Functional sequences (diffusion, perfusion)
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
  • Subjective scoring
  • Single-site sampling misses heterogeneity
  • Tissue quantity
  • VUS interpretation
  • 2-3 week turnaround
  • Non-specific: infection and inflammation are also hot
  • Brain background
  • Poor in indolent tumours
  • Slow and expensive
  • Motion artefacts
  • Gadolinium concerns in renal impairment
Questions to ask about this decision
  1. Between Histopathology & immunohistochemistry, Comprehensive genomic profiling, FDG PET and the other options, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (Consensus recommendations for Rosai-Dorfman-Destombes disease (Blood 2018)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (diagnosis and staging), which of the standard options do you recommend and why?
    Why: Guideline options include: Excisional biopsy with immunohistochemistry and MAPK pathway sequencing; FDG-PET/CT; MRI where neurological disease is suspected; immunoglobulins and autoimmune screen.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Asymptomatic nodal or cutaneous disease

One path named

Observation, because spontaneous regression is common.

The path, in plain words
Active surveillanceStandard of care

For low-risk prostate cancer, monitoring with PSA, MRI, and repeat biopsy instead of treating, because most such cancers never cause harm.

  • Avoids incontinence and erectile dysfunction of treatment in men who would never be harmed
  • Level-1 evidence of safety (ProtecT)
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
  • Anxiety and adherence
  • Repeat biopsies
  • Under-used outside high-income countries
Questions to ask about this decision
  1. Is Active surveillance the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
    Why: A single standard does not mean a single choice; timing and trials are decisions too.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (Consensus recommendations for Rosai-Dorfman-Destombes disease (Blood 2018)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (asymptomatic nodal or cutaneous disease), which of the standard options do you recommend and why?
    Why: Guideline options include: Observation, because spontaneous regression is common.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Single or compressive extranodal lesion

One path named

Surgical excision or debulking; radiotherapy for unresectable localised disease (orbit, airway).

The path, in plain words

IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.

  • Conformal dose, fewer side effects
  • Hypofractionation saves visits
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
  • Low-dose bath to normal tissue
  • Motion management
Questions to ask about this decision
  1. Is IMRT / IGRT (modern external beam) the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
    Why: A single standard does not mean a single choice; timing and trials are decisions too.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (Consensus recommendations for Rosai-Dorfman-Destombes disease (Blood 2018)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (single or compressive extranodal lesion), which of the standard options do you recommend and why?
    Why: Guideline options include: Surgical excision or debulking; radiotherapy for unresectable localised disease (orbit, airway).

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Multifocal or organ-threatening disease

Corticosteroids for rapid control; sirolimus with prednisone, cladribine, methotrexate or lenalidomide; rituximab for IgG4-associated disease.

The options, in plain words

A one-week infusion that puts most people with hairy cell leukaemia into remission for years; also used in multiple sclerosis in tablet form.

The 1948 antifolate that produced the first chemotherapy remissions in childhood leukaemia and the first cure of a solid tumour; still essential in ALL, lymphoma, osteosarcoma and CNS lymphoma.

Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
  • High-dose methotrexate requires normal renal function, hydration, urine alkalinisation and leucovorin rescue with level monitoring.
Side effectAny gradeGrade 3+
Infusion-related reactions (first infusion) · Historic lymphoma data; lower with premedication77%-

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Questions to ask about this decision
  1. Between Cladribine, Methotrexate and Rituximab, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. Which side effects of Rituximab are most likely for me, which are reversible, and which would make us stop?
    Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
  4. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  5. Does your recommendation follow the current guideline (Consensus recommendations for Rosai-Dorfman-Destombes disease (Blood 2018)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  6. For my situation (multifocal or organ-threatening disease), which of the standard options do you recommend and why?
    Why: Guideline options include: Corticosteroids for rapid control; sirolimus with prednisone, cladribine, methotrexate or lenalidomide; rituximab for IgG4-associated disease.
  7. Am I a candidate for Cladribine, Methotrexate, Rituximab, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

Third line and beyond

MAPK-mutant or refractory disease

2 options

Cobimetinib (approved 2022 for histiocytic neoplasms) or trametinib.

The options, in plain words

Cobimetinib is the MEK partner for vemurafenib, and the first drug approved for histiocytic neoplasms.

Pills that block the specific enzyme a cancer relies on. Imatinib in 2001 proved a cancer could be switched off by design.

  • Oral, outpatient
  • Dramatic responses in oncogene-addicted cancers
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
  • Near-universal resistance in metastatic disease
  • Off-target toxicities
Questions to ask about this decision
  1. Between Cobimetinib and Small-molecule kinase inhibitors, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (Consensus recommendations for Rosai-Dorfman-Destombes disease (Blood 2018)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (mapk-mutant or refractory disease), which of the standard options do you recommend and why?
    Why: Guideline options include: Cobimetinib (approved 2022 for histiocytic neoplasms) or trametinib.
  6. Am I a candidate for Cobimetinib, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.